BRAF and colorectal carcinoma: In such manner, the RAF-coding gene, BRAF, which is also found to be mutated in 9–15% [33,109] of CRC and usually associated with poor prognosis [33], limited response to standard-of-care therapies [148], and with an increased kinase activity in sporadic CRC with microsatellite instability [109], would also be a valuable biomarker.